Can anything shut down the Gold rally?
DUBLIN - Fusion Fuel Green PLC (NASDAQ:HTOO), a company specializing in gas and hydrogen energy solutions, has announced the appointment of Luisa Ingargiola to its Board of Directors, effective as of last Monday. Ingargiola will assume the role of chairperson of the Audit Committee, succeeding Rune Magnus Lundetrae who will stay on as a board member. Additionally, she will join the Nominating Committee and Compensation Committee.
The board expansion brings the total number of directors to six, with four meeting the Nasdaq’s independence criteria. Jeffrey Schwarz, Chairman of Fusion Fuel, expressed confidence in Ingargiola’s appointment, citing her extensive background in public company governance and financial oversight as beneficial for Fusion Fuel’s strategic and financial endeavors.
Ingargiola currently holds the position of Chief Financial Officer at Avalon GloboCare Corp. (NASDAQ:ALBT), which has seen remarkable stock performance with a 155% year-to-date return and 96% gain over the past six months. According to InvestingPro analysis, ALBT appears overvalued at current levels, with a weak overall financial health score. Discover 10+ additional exclusive insights and real-time metrics with InvestingPro’s comprehensive analysis tools. Ingargiola also serves on the board of Vision Marine Technologies , Inc. (NASDAQ:VMAR) and BioCorRx Inc. (OTCQB:BICX), where she also chairs the Audit Committees. Her previous experience includes co-founding and serving as CFO of BBHC, Inc., known before as MagneGas Corporation.
Fusion Fuel Green PLC operates through its subsidiaries, Al-Shola Gas and BrightHy, providing energy engineering and advisory solutions. Al-Shola Gas offers industrial gas solutions, including LPG system design and supply, while BrightHy focuses on hydrogen solutions for decarbonizing industries.
This announcement is based on a press release statement from Fusion Fuel Green PLC.
In other recent news, Avalon GloboCare Corp. has finalized a significant financial transaction by selling its 40% equity interest in Laboratory Services MSO, LLC for $1.745 million. This transaction involves an initial payment of $95,000, followed by monthly installments starting in March 2025. Furthermore, Avalon has secured a $7 million agreement with York Sun Investment Holding Limited for the sale of Series C Convertible Preferred Stock, with an initial $3.5 million transaction already completed. In another development, Avalon exchanged 9,000 shares of Series A Preferred Stock for 5,000 shares of newly designated Series D Preferred Stock with its Chairman, Wenzhao Lu, effectively retiring the Series A Preferred Stock. Additionally, the company has received a Notice of Allowance from China for a patent application related to its CAR therapy technology, co-developed with Arbele Limited. This patent focuses on enhancing CAR-T and CAR-NK cell therapies. These developments reflect Avalon’s ongoing efforts to optimize its asset portfolio and expand its intellectual property rights.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.